Management of Immunotherapy-Related Toxicities, Version 1.2022

Academic Article


  • The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Thompson JA; Schneider BJ; Brahmer J; Achufusi A; Armand P; Berkenstock MK; Bhatia S; Budde LE; Chokshi S; Davies M
  • Start Page

  • 387
  • End Page

  • 405
  • Volume

  • 20
  • Issue

  • 4